Researchers from the Wellcome Trust Sanger Institute have identified a host receptor, basigin Ok blood group, that could be a good candidate for a vaccine against blood-stage malaria infection. The vaccine could be more effective at preventing clinical symptoms than vaccines that target the asymptomatic liver stage of the parasite.